Unilife has posted a net loss of $9.7m or $0.18 per diluted share, compared to net loss of $2.2m, or $0.06 per diluted share for the same period in 2009.
For the full year ended 30 June 2010 Unilife reported revenues of $11.4m compared to $20m for the same period in 2009.
Unilife has also posted a net loss of $29.7m or $0.64 per diluted share for the full year ended 30 June 2010 compared to a net loss of $0.5m, or $0.02 per diluted share for the same period in 2009.
Unilife CEO Alan Shortall said that Fiscal 2010 has been a pivotal year for Unilife and they are working to finalise the industrialisation of the Unifill syringe and expand relationships with interested pharmaceutical companies, accelerate the global rollout of our Unitract 1ml syringes and complete the construction of new facility in York, Pennsylvania.
“We remain committed to the continued implementation of our business strategy, and the execution of a number of significant business milestones during fiscal 2011,” Shortall said.
